ERCC-1 1 and response to chemotherapy. Jean-Charles SORIA, MD, PhD Institut Gustave Roussy

Size: px
Start display at page:

Download "ERCC-1 1 and response to chemotherapy. Jean-Charles SORIA, MD, PhD Institut Gustave Roussy"

Transcription

1 ERCC-1 1 and response to chemotherapy 1 Jean-Charles SORIA, MD, PhD Institut Gustave Roussy

2 Cancer and Chemotherapy: the exemple of Lung Cancer 2 50 CT + supportive care 40 Surgery ± CT Patients (%) RT ± CT 0 Localised Regional Distant RT = radiotherapy CT = chemotherapy

3 Platin-based chemotherapy is the mainstay of first-line treatment for NSCLC Cisplatin/paclitaxel Cisplatin/gemcitabine Cisplatin/docetaxel Carboplatin/paclitaxel Months Schiller JH, et. al. N Engl J Med 2002;346:92 8

4 4

5 Platinum derivatives and DNA repair pathway 5 Platinum cytotoxic effects are related to DNA binding and DNA adducts Nucleotide excision repair (NER) plays a central role in DNA repair pathways ERCC1 enzyme plays a rate-limiting role in the NER pathway In vitro and clinical studies suggest a relation between ERCC1 mrna and response to cisplatin

6 ERCC1 is a rate-limiting partner in the NER pathway 6 Gazdar et al, New England J Med 2007

7 Platinum resistance in vitro 7 ERCC1 mrna or protein expression levels correlate with cisplatin resistance in human cancer cell lines Cancer cell lines ERCC1 expression Phenotypic effets ovarian mrna (3-fold ) Cisplatine resistance ovarian mrna and protein (2-fold ) Repair of cisplatin-dna adducts ovarian ERCC1 anti-sense mrna Restored sensitivity to cisplatine ovarian ERCC1 SiRNA > 53-fold in cisplatin sensitivity cervical mrna Positively correlated with oxaloplatine resistance testis protein Low levels of ERCC1 compared with other cell lines lung ERCC1 anti-sense mrna Decreased the repair capacity Gossage et al, Cancer Treat Rev. 2007

8 ERCC1 as a predictive and/or prognostic marker in human cancers Cancer type Number of patients Treatment ERCC1 expression Resected NSCLC 761 Adjuvant cisplatin-based therapy Protein Resected NSCLC 51 Majority received no chemotherapy mrna 8 Advanced NSCLC 70 G(gemcitabine)/C or C(cisplatin) mrna Advanced NSCLC >400 Randomized to D/C, or D/C if ERCC1 or D/C if ERCC1 mrna Advanced NSCLC 56 G/C mrna Advanced colorectal cancer 50 5FU/oxaliplatin mrna Advanced colorectal cancer 33 Irinotecan mrna Advanced gastric cancer 64 Oxaliplatin/5FU Protein Operable gastric cancer 38 Neoadjuvant C(/F mrna Oesophageal cancer 99 Neoadjuvant CRT(chemoradiotherapy) (C/F) mrna Oesophageal cancer 36 Neoadjuvant CRT (C/F) mrna Ovarian cancer 26 Platinum based therapy mrna Ovarian cancer 28 Platinum based therapy mrna Advanced bladder cancer 57 G/C or G/C/P mrna Gossage et al, Cancer Treat Rev. 2007

9 ASCO 2003: International Adjuvant Lung Trial patients with completely resected NSCLC I-II-IIIA Absolute benefit : 4.1% improvement of 5 year OS 100% 80% HR= 0.86 [ ] p< % 40% 20% 0% The IALT Collaborative Group, NEJM 2004

10 ASCO 2006: IALT-bio study ERCC1: a predictor of chemotherapy benefit? 10 All IALT centers 1867 pts IALT Centers > 10 patients 1045 pts 867 blocks received 783 exploitable NSCLC (after pathological review) 761 patients evaluable for ERCC1

11 Methods: ERCC1 immunohistochemistry 11 Immunohistochemical analysis Standardized antigen retrieval ERCC1 monoclonal antibody (NeoMarkers) Evaluation of staining by two independent investigators, blinded to clinical data Internal controls (normal tissue) Staining intensity and percentage of positive cells (H-score)

12 ERCC1 negative ERCC1 positive 12

13 Predictive Analysis 13 Test of interaction ERCC1 treatment: p = Chemotherapy n=389 5-year survival rate, Control group n=372 5-year survival rate, Hazard ratio for death CT vs. no CT Median survival Median survival ERCC1 negative tumors n=426 47% [40%-55%] 56 months 39% [32%-47%] 42 months 0.65 [ ] p = ERCC1 positive tumors n=335 40% [32%-49%] 50 months 46% [37%-55%] 55 months 1.14 [ ] p = 0.40 Gain of 14 months of overall survival from adjuvant chemotherapy in patients with ERCC1 negative tumor

14 Effect of adjuvant chemotherapy on overall survival in pts with ERCC1 negative tumor 14 Overall Survival 100% 80% 60% 40% 20% Control (113 deaths) Chemotherapy (105 deaths) No at risk Chemotherapy Control 0% Years Adjusted HR=0.65, 95%CI [ ], 0.86], p = 0.002

15 Effect of adjuvant chemotherapy on overall survival in pts with ERCC1 positive tumor 15 Overall Survival 100% 80% 60% 40% 20% Chemotherapy (92 deaths) Control (80 deaths) No at risk Chemotherapy Control 0% Years Adjusted HR=1.14, 95%CI [ ], P = 0.40

16 Prognostic analysis 16 In the control group, ERCC1 positive patients have a favorable prognosis HR * 95% CI P value Control group ERCC1 negative 1 ERCC1 positive 0.66 [ ] 0.90] Chemotherapy ERCC1 negative 1 ERCC1 positive 1.16 [ ] 0.34 All patients ERCC1 negative 1 ERCC1 positive 0.88 [ ] 1.10] 0.26

17 Results 17 ERCC1 negative ERCC1 positive Benefit of Cisplatin-based CT in ERCC1 NEGATIVE patients Olaussen et al, New England J Med 2006

18 18 Prognostic value of ERCC1 and RRM1 in stage I NSCLC patients

19 GILT: the first ERCC1-based customized chemotherapy 19 R A N D O M I Z E Control arm docetaxel / cisplatin Cisplatin 75 mg/m2 day 1 Docetaxel 75 mg/m2 day 1 Experimental arm ERCC1 levels RT-PCR Advanced NSCLC Microdissection then RT-PCR docetaxel / cisplatin (low ERCC1 mrna) Cisplatin 75 mg/m2 day 1 Docetaxel 75 mg/m2 day 1 gemcitabine / docetaxel (high ERCC1 mrna) Docetaxel 40 mg/m2 day 1, 8 Gemcitabine 1000 mg/m2 day 1,8 Rosell et al. ESMO 2006

20 GILT: ERCC1-based customized chemotherapy 20 Projected accrual patients randomized : 283 patients enrolled 17% dropped out! Of which 57% due to insufficient tissue An additional 102 patients were included Total randomized 444 and 366 enrolled Still 17% dropped out

21 GILT: ERCC1-based customized chemotherapy 21 Response rate Statistical difference (p=0.02) 39% in control vs. 51% in genotypic OR in ERCC1 low: 53.7% OR in ERCC1 high: 47.2% No difference in complete response rate 4.3% in control vs 3.1% in genotypic No differences in OS or PFS

22 GILT: ERCC1-based customized chemotherapy 22 Trial initiated in the early 2000s: visionary and extremely audacious! Why is this trial negative? Did ERCC1 failed in identifying patients who should receive cisplatin based chemotherapy? Docexatel-gemcitabine the best non-platinum combination? The control arm received the same chemotherapy as the low ERCC1 and no data on ERCC1 are known in the control arm It would have been better to prospectively confirm that low ERCC1 expressors respond better than high ERCC1 expressors to one platinum combination Methodological and technological issues complicate the interpretation of the study Reproductibility high drop out rate

23 Predictive biomarkers of Ct efficacy 23 Cisplatin Gemcitabine Pemetrexed Paclitaxel Docetaxel ERCC1 RRM1? RRM1? FPGS? MAPtau? Bcl2?

24 ERCC1 open questions 24 Clinical questions Validation of ERCC1 predictive value Molecular and clinical characterization ERCC1 pos/neg pts Future clinical trials Other tumor types Biological questions ERCC1 partners (XPF, XPA, RPA ) Biological function of ERCC1 Regulation of ERCC1 gene expression Methodological perspectives

25 External validation of ERCC1 expression predictive/prognostic prognostic value 25 Assuming 200 patients for BR10 and 400 patients for Anita

26 Clinical characterization of ERCC1 neg/pos pts 26 Brain metastasis are increased in ERCC1 NEG patients treated by CT (non squamous histology, n=335) ERCC1 NEG ERCC1 POS 1,00 0,80 0,60 Control Chemotherapy 1,00 0,80 0,60 Control Chemotherapy 0,40 0,40 0,20 0,20 At risk 0,00 0, Years Years At risk Besse et al. ASCO 2007 Brain metastasis occurrence according to treatment

27 Future clinical trials 27 Design and implement a customized trial of adjuvant Ct integrating ERCC1 data should ERCC1 be associated with other markers (EGFR mut/fish?) to which compounds ERCC1 positive and negative patients are the most likely to respond (beyond cisplatin) should ERCC1 positive patients get a treatment?

28 NSCLC pt1(x>2cm) pt2n0m0 R0 resection SWOG Pilot Study: Pharmacogenomic-directed Adjuvant Therapy of NSCLC RRMI > 40.5 AND ERCC1> 66.0 All Others (RRM1< 40.5 OR ERCC1 < 66.0 ) 28 Age PS 0-10 N~TBD Active Monitoring PI: Bepler Cisplatin-Gemcitabine

29 French adjuvant lung cancer study (IFCT) 29 ARM A (Standard) CDDP doublet EGFR+ Erlotinib ERCC1+ EGFR- No treatment ARM B Customized Bio - Chemo ERCC1- EGFR + EGFR- CDDP doublet followed by erlotinib CDDP doublet

30 ERCC1: open questions 30 Clinical questions Validation of ERCC1 predictive value Molecular and clinical characterization ERCC1 pos/neg pts Future clinical trials Other tumor types Biological questions ERCC1 partners (XPF, XPA, RPA ) Biological function of ERCC1 Regulation of ERCC1 gene expression Methodological perspectives

31 ERCC1 partners in cancer 31 XPF RPA

32 Possible ERCC1 target sites 32 Protein-Protein XPF/ERCC1 Protein-Protein XPA/ERCC1 XPF ERCC1 Protein-DNA K.Tripsianes et al, Nucleic Acids Research, 2007

33 ERCC1 gene expression regulation 33

34 34 Conclusions ERCC1 expression is a predictive factor of chemotherapy benefit in patient treated by cisplatin-based adjuvant chemotherapy ERCC1 expression is a prognostic factor in patient not treated by chemotherapy ERCC1 plays a fundamental function in drug resistance and cancer susceptibility (Janus-faced of ERCC1)

35 35 Conclusions Personalized medicine is one of the strongest expectations from patients and health-care takers The next step integration of the best biomarkers in prospective trials implementation of pharmacogenomic-based clinical trials

36 Acknowledgements 36 Laboratory Investigators Christophe Raynaud Pierre Fouret Laure Sabatier Elisabeth Brambilla Ken Olaussen David Planchard Estelle Taranchon Clinicians Statisticians Julien Domont Christophe Massard Pierre Validire Benjamin Besse Vincent Haddad Ariane Dunant Jean-Pierre Pignon Catherine Hill Fabrice André

Is the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials

Is the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized

More information

Systemic therapy in early stage NSCLC. Disclosures

Systemic therapy in early stage NSCLC. Disclosures Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany

More information

11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients

11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research

More information

Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist

Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage

More information

Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico

Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II

More information

Heather Wakelee, M.D.

Heather Wakelee, M.D. Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.

More information

Prognostic and predictive biomarkers in

Prognostic and predictive biomarkers in OLOGICAL SCIENCES O DEPT. OF CLINICAL & BIO UNIVERSITY UNIVERSTY OF TORINO Prognostic and predictive biomarkers in early stage NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical &

More information

The Evolving Role of Adjuvant Therapies

The Evolving Role of Adjuvant Therapies Therapy-predictive markers for adjuvant chemotherapy The Evolving Role of Adjuvant Therapies Micrometastasis Prognostic Markers (BRCA1) Cured No Further Tx Chemosensitive Rafael Rosell th European Perspectives

More information

Adjuvant Chemotherapy

Adjuvant Chemotherapy State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant

More information

Combined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago

Combined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy

More information

Optimal Application of Adjuvant Therapy in NSCLC

Optimal Application of Adjuvant Therapy in NSCLC Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial Stage n Chemo

More information

PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France

PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative

More information

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug

More information

Adjuvant Chemotherapy for Non-small Cell Lung Cancer

Adjuvant Chemotherapy for Non-small Cell Lung Cancer PISA SYMPOSIUM Adjuvant Chemotherapy for Non-small Cell Lung Cancer Emilio Bria, MD, Federica Cuppone, MD, Fabiana Letizia Cecere, MD, Michele Milella, MD, Cecilia Nisticò, MD, Francesco Cognetti, MD,

More information

Slide 1. Slide 2 Post 1995 Meta-Analysis : Slide 3

Slide 1. Slide 2 Post 1995 Meta-Analysis : Slide 3 Slide 1 Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Slide 2 Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial

More information

PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy

PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome

More information

Adjuvant Therapy in NSCLC. Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia

Adjuvant Therapy in NSCLC. Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia Adjuvant Therapy in NSCLC Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia Agenda What do we expect today from new adjuvant chemotherapy Which data do we have with targeted agents

More information

Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We

Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David

More information

LUNG CANCER TREATMENT: AN OVERVIEW

LUNG CANCER TREATMENT: AN OVERVIEW LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor

More information

ESMO Preceptorship Programme NSCLC Singapore 15 November 2017

ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA

More information

Thoracic and head/neck oncology new developments

Thoracic and head/neck oncology new developments Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening

More information

Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?

Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive

More information

The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer

The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer Nathan A. Pennell, M.D., Ph.D. Assistant Professor Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute www.cancergrace.org

More information

EGFR inhibitors in NSCLC

EGFR inhibitors in NSCLC Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance

More information

State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy?

State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy? ESMO Preceptorship Programme NSCLC Singapore 13 14 dec 2016 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy? Pr Jaafar BENNOUNA

More information

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease

More information

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive

More information

Maintenance paradigm in non-squamous NSCLC

Maintenance paradigm in non-squamous NSCLC Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons

More information

Lung Cancer Epidemiology. AJCC Staging 6 th edition

Lung Cancer Epidemiology. AJCC Staging 6 th edition Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON

More information

ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine

ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from

More information

The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.

The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:

More information

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr.

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy

More information

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),

More information

Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute

Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts

More information

Slide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy

Slide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University

More information

Neodjuvant chemotherapy

Neodjuvant chemotherapy Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional

More information

Adjuvant therapy of NSCLC: where to go from here?

Adjuvant therapy of NSCLC: where to go from here? SAMO Winter Workshop on Chest Tumours Adjuvant therapy of NSCLC: where to go from here? J Vansteenkiste Dept Pulmonology Leuven Lung Cancer Group > adjuvant therapy ± 1,200,000 lung cancers worldwide >80%

More information

Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer

Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer Review Article Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer Robert Pirker Department of Medicine I, Medical University of Vienna, Vienna, Austria Correspondence

More information

Medical Treatment of Advanced Lung Cancer

Medical Treatment of Advanced Lung Cancer Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics

More information

Practice changing studies in lung cancer 2017

Practice changing studies in lung cancer 2017 1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received

More information

Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy

Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Anna Dorothea Wagner, PD & MER Department of Oncology University of Lausanne Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Structure 1. Background and overview 2. Adjuvant chemotherapy:

More information

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University 2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling

More information

Immunotherapy in head and neck cancer and MSI in solid tumors

Immunotherapy in head and neck cancer and MSI in solid tumors Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology

More information

1st line chemotherapy and contribution of targeted agents

1st line chemotherapy and contribution of targeted agents ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy

More information

ALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials

ALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:

More information

1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC

1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC 1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science

More information

Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?

Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology

More information

Medicinae Doctoris. One university. Many futures.

Medicinae Doctoris. One university. Many futures. Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All

More information

Individualized Adjuvant Chemotherapy for Surgically Resected Lung Cancer and the Roles of Biomarkers

Individualized Adjuvant Chemotherapy for Surgically Resected Lung Cancer and the Roles of Biomarkers Review Individualized Adjuvant Chemotherapy for Surgically Resected Lung Cancer and the Roles of Biomarkers Norihiko Ikeda, MD, Seisuke Nagase, MD, and Tatsuo Ohira, MD Several prospective randomized trials

More information

Lung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium

Lung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Lung cancer in the elderly D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Incidence and mortality of all cancers and lung cancer in relation to age and gender (US) 120,000

More information

Histology in the Decision-making Process

Histology in the Decision-making Process Histology in the Decision-making Process Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it Lung Cancer Four Main Histological Subtypes

More information

Disclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?

Disclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first? Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant

More information

K-Ras signalling in NSCLC

K-Ras signalling in NSCLC Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer

More information

SAMO MASTERCLASS HEAD & NECK CANCER. Nicolas Mach, PD Geneva University Hospital

SAMO MASTERCLASS HEAD & NECK CANCER. Nicolas Mach, PD Geneva University Hospital SAMO MASTERCLASS HEAD & NECK CANCER Nicolas Mach, PD Geneva University Hospital Epidemiology Prevention Best treatment for localized disease Best treatment for relapsed or metastatic disease Introduction

More information

NSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy

NSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local

More information

Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)

Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic

More information

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical

More information

EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS

EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain

More information

Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007

Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard

More information

Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel

Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,

More information

The road less travelled: what options are available for patients with advanced squamous cell carcinoma?

The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting

More information

Lung Cancer Working Group Report

Lung Cancer Working Group Report Jpn J Clin Oncol 2010;40(Supplement 1)i7 i12 doi:10.1093/jjco/hyq121 Original Articles Nagahiro Saijo 1,*, Masahiro Fukuoka 2, Sumitra Thongprasert 3, Yukito Ichinose 4, Tetsuya Mitsudomi 5, Tony Shu Kam

More information

Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer

Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern

More information

RESEARCH ARTICLE. ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy

RESEARCH ARTICLE. ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy RESEARCH ARTICLE ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy Mohamed Ali EL Baiomy 1 *, Wagdi F El Kashef 2 Abstract Background: Possible

More information

1st-line Chemotherapy for Advanced disease

1st-line Chemotherapy for Advanced disease SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS

More information

GASTRIC & PANCREATIC CANCER

GASTRIC & PANCREATIC CANCER GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org

More information

FoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV

FoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common

More information

Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy

Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a

More information

Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer

Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm

More information

Lymph node metastasis is the most important prognostic

Lymph node metastasis is the most important prognostic ORIGINAL ARTICLE Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and III-Tubulin Between Primary Non-small Cell Lung Cancer

More information

continuing education Non-small cell lung cancer: Molecular targets and emerging options for care Daniel Morgensztern, MD

continuing education Non-small cell lung cancer: Molecular targets and emerging options for care Daniel Morgensztern, MD continuing education educational objectives After participating in this activity, clinicians should be better able to Perform diagnostic/molecular testing (EGFR, KRAS, EML4-ALK) for NSCLC according to

More information

Individualized therapy in lung cancer Where are we in 2012?

Individualized therapy in lung cancer Where are we in 2012? UNIVERSITY OF OF TORINO DEPARTMENT OF ONCOLOGY Individualized therapy in lung cancer Where are we in 2012? Giorgio V. Scagliotti University of Torino Professor of Medical Oncology Department of Oncology

More information

GCIG Rare Tumour Brainstorming Day

GCIG Rare Tumour Brainstorming Day GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial

More information

Selection of systemic therapy in Advanced NSCLC based on biological factors. State of the Art

Selection of systemic therapy in Advanced NSCLC based on biological factors. State of the Art Selection of systemic therapy in Advanced NSCLC based on biological factors State of the Art Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it

More information

Advances in gastric cancer: How to approach localised disease?

Advances in gastric cancer: How to approach localised disease? Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation

More information

Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens

Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens 1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days

More information

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in

More information

Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer?

Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer? Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer? ~A pooled analysis of the literature~ Satomi Yamamoto 1, Kazuyuki

More information

Carcinosarcoma Trial rial in s a in rare malign rare mali ancy

Carcinosarcoma Trial rial in s a in rare malign rare mali ancy Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with

More information

Stage III NSCLC: Overview

Stage III NSCLC: Overview Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview

More information

Chemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002

Chemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002 Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women

More information

NSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza

NSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine

More information

Gastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.

Gastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D. Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation

More information

MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf

MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance

More information

Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma

Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma M.J. Wang, Y. Zhu, X.J. Guo and Z.Z. Tian Department of Orthopaedics, Xinxiang Central Hospital, Xinxiang,

More information

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately

More information

Debate on stage III NSCLC: The role of systemic therapy

Debate on stage III NSCLC: The role of systemic therapy 1 Debate on stage III NSCLC: The role of systemic therapy Rolf Stahel University Hospital of Zürich Bucharest, 16.6..2015 2 Stage III disease: The problem of heterogeneity, the risk of distant metastases

More information

CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER

CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,

More information

Single Technology Appraisal (STA)

Single Technology Appraisal (STA) Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response

More information

Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma

Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca

More information

Non-small cell lung cancer (NSCLC) is the leading cause

Non-small cell lung cancer (NSCLC) is the leading cause Original Article ERCC1 and BRAC1 mrna Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small

More information

Lung cancer update 2007

Lung cancer update 2007 Lung cancer update 2007 HARMESH R NAIK, MD. January 24, 2007 Epidemiology (world) Estimated 1.35 million new cases in world in 2002 Estimated 1.179 million deaths in world in 2002 Common cancer diagnosis

More information

Combined modality treatment for N2 disease

Combined modality treatment for N2 disease Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical

More information

Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer

Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual

More information

Heterogeneity of N2 disease

Heterogeneity of N2 disease Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity

More information

Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy

Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics

More information

Head and Neck Cancer:

Head and Neck Cancer: Head and Neck Cancer: Robert Haddad M.D. Clinical Director Head and Neck Oncology Program Dana Farber Cancer Institute Boston, MA Predictive Biomarkers: HPV Abstract 6003: Survival Outcomes By HPV Status

More information

Expression of ERCC1, MSH2 and PARP1 in Non-small Cell Lung Cancer and Prognostic Value in Patients Treated with Platinum-based Chemotherapy

Expression of ERCC1, MSH2 and PARP1 in Non-small Cell Lung Cancer and Prognostic Value in Patients Treated with Platinum-based Chemotherapy DOI:http://dx.doi.org/10.7314/APJCP.2014.15.6.2591 Prognostic Value of ERCC1 and PARP1 in NSCLC Cases Undergoing Platinum-based Chemotherapy RESEARCH ARTICLE Expression of ERCC1, MSH2 and PARP1 in Non-small

More information

Introducción. Enric Carcereny ICO Badalona-Hospital Germans Trias i Pujol

Introducción. Enric Carcereny ICO Badalona-Hospital Germans Trias i Pujol Introducción Enric Carcereny ICO Badalona-Hospital Germans Trias i Pujol Introducción Cáncer de pulmón: la neoplasia más frecuente y la principal causa de muerte relacionada con el cáncer. GLOBOCAN 2012

More information

Neo-adjuvant chemotherapy in NSCLC

Neo-adjuvant chemotherapy in NSCLC SCLC Epidemiology eo-adjuvant chemotherapy in SCLC Sarita Dubey sst Professor, Medical ncology, UCSF UCSF/UC Davis Thoracic conference ovember 8, 2008 Statistics for 2008 Cancer Incidence Deaths Colon

More information